WHC is still in active development. Read this to understand our approach.
depiction of LNEPOXFFQSENCJ-UHFFFAOYSA-N.svg
psychonaut

Haloperidol

Check on psychonaut

isomerdesign

Haloperidol

Check on isomerdesign

pubchem

Haloperidol

Check on pubchem

drugmap

Haloperidol

Check on drugmap

drugmap

Haloperidol

Check on drugmap

wiki

Haloperidol

Check on wiki

Data

InChI: InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

Synonyms: n--boc-l-asparagine,MRF-0000027,NSC-615296,R-1625,Spectrum4_000570,HMS2234P08,KBioSS_002395, Sigaperidol,AKOS000280660,SPBio_001236, Serenace (TN),R 1625,Haloperidol (JP17/USP/INN),NCGC00023875-04, Linton,BRD-K67783091-001-04-8, Aloperidolo, Mixidol,Poly[2-methoxy-5-(3',7'-dimethyloctyloxy)-1,4-phenylenevinylene],A899749, Lealgin compositum,BRN 0331267,Butyrophenone, 4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4'-fluoro-,KBio2_004958,BH166165,Spectrum3_000448,NCGC00023875-07, Haloperidol [USAN:INN:BAN:JAN],Bioperidolo, Aloperidin (TN), Peridol,HMS2089M15,HMS2095G12,Sigaperidol,Probes1_000255,GTPL86,NCGC00015500-06,CCG-36042, Dozix,1-(3-p-Fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine, Ulcolind,HMS3657I13,Aloperidolo [DCIT],BSPBio_002096,NCGC00015500-13, McN-JR-1625,FT-0669101,1-Butanone, 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-,Haloperidol (Haldol),Haloperidol, United States Pharmacopeia (USP) Reference Standard, Haldol,SW196557-4,N1910,Halopoidol,4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl) -1-butanone,BIDD:GT0128, Haloperidol (JP15/USP),NCGC00023875-02, Keselan,KBio2_007526,CCG-39111,Duraperidol,Butyrophenone, 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-,Haloperidol-[Chlorophenyl-d4],SDCCGSBI-0050565.P005, Galoperidol,5-21-02-00377 (Beilstein Handbook Reference),NCGC00015500-14,H0912,Tox21_110162_1,AB00052008_24,Ulcolind, Aloperidolo [DCIT],BRD-K67783091-001-05-5, Bioperidolo (TN),EINECS 200-155-6,4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone,Haldol (TN),Biomol-NT_000035, Brotopon,NSC170973,HALOPERIDOL [USAN],NINDS_000654, H 1512,NCGC00015500-10,4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone,KBio2_001341,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one;propionate(HCl),NCGC00261268-01,MLS000028450, Duraperidol (TN),NCGC00015500-07,VU0239704-10,Serenace,Haloperidol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Serenase (TN),KBio3_001316,Pernox,ZINC537822,NCGC00015500-15,HALOPERIDOL [MI],4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one,NCGC00015500-17, Serenelfi,VESALIUM COMPONENT HALOPERIDOL,NCGC00015500-01,KBioGR_000980, Dozic (TN),4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one, Halopidol, Aldo,HALOPERIDOL DECANOATE IMPURITY G [EP IMPURITY],Galoperidol,Spectrum5_000788,cMAP_000037, Sernas,Halol,HALOPERIDOL [WHO-DD],Haloperidol for system suitability, European Pharmacopoeia (EP) Reference Standard,HALOPERIDOL [ORANGE BOOK],Prestwick1_000115, Serenace,Prestwick3_000115,HALOPERIDOL [INN],IDI1_000654,HALOPERIDOL [MART.],SR-01000003076-11, Halol,Haloperidol 1.0 mg/ml in Methanol,Epoxy resins,Halosten,Serenelfi,Halopal,WLN: T6NTJ A3VR DF& DQ DR DG,52-86-8,Aldo,KBio1_000654,Sernas,NSC757054,Q251347, Halosten,NCGC00015500-19, Haldol La,Haldol,Aloperidolo [Italian], Halosten (TN),Opera_ID_446,NCGC00015500-12,NSC 615296,BPBio1_001231,Probes2_000296,SPECTRUM1500325,Haloperidol, 1,LNEPOXFFQSENCJ-UHFFFAOYSA-,HALOPERIDOL DECANOATE IMPURITY, HALOPERIDOL- [USP IMPURITY], Aloperidolo [Italian], Sernel,KBio2_006477,4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)butan-1-one,Haloperidol decanoate impurity, haloperidol-,AC-19691,Lopac0_000583,NCGC00023875-05,L000288,Lealgin compositum,starbld0018801, Einalon S,BSPBio_000130,DSSTox_RID_79117,AB00052008,NSC-757054,NCGC00023875-09,4-[4-(para-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone,D00136,AC250,Butyrophenone, 4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-4'-fluoro-, Haloperidolum [INN-Latin],Aloperidol, Pekuces,Poly[[2-[(3,7-dimethyloctyl)oxy]-5-methoxy-1,4-phenylene]-1,2-ethenediyl],DivK1c_000654,MLS001146904,NCGC00015500-09,Haloperidol [USAN:USP:INN:BAN:JAN], Halidol,4-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone, R-1625,STR04750,NCGC00015500-11,KBioGR_002390,Prestwick_250, Apo-Haloperidol, Serenase,Aloperidolo,NCGC00023875-08, Linton (TN),Haloperidol for peak identification, Keselan (TN), Haloperidol (JP15/USP/INN),gamma-(4-(p-Chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone,Haloperidol, European Pharmacopoeia (EP) Reference Standard,Sernel, Brotopon (TN), Haloperido,KBio3_002869,4'-Fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone,UNII-J6292F8L3D,gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorbutyrophenone, Dozic,Uliolind,NCGC00015500-02,SPBio_002069,Keselan, Haldol Solutab,CS-1971,Prestwick2_000115,AB00052008-21,HMS3712G12,4'-Fluoro-4-(4-hydroxy-4-p-chlorophenylpiperidino)butyrophenone,EU-0100583,Spectrum_000861,CHEMBL54,Haldol Solutab, Haldol (TN),4-(4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone,FT-0697842,4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)butan-1-one,haloperidol,NCGC00015500-24,SC 170973,Tox21_500583,H 1512,1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-,Haloperidolum,.gamma.-[4-(p-Chlorphenyl)-4-hydroxpiperidino]-p-fluorbutyrophenone,QTL1_000042,Novo-Peridol,DSSTox_GSID_34150,Aloperidin, Bioperidolo,AB00052008-22,Einalon S,BRD-K67783091-003-03-6,4-(4-(para-Chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone, Aloperidon,HMS3261F08,BPBio1_000144,NCGC00015500-32,CAS-52-86-8,KBio2_002390,gamma-[4-(p-chlorophenyl)-4-hydroxypiperidino]-p-fluorobutyrophenone,DB00502,HALOPERIDOL [EP MONOGRAPH],LP00583,.gamma.-(4-(p-Chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone,NCGC00254503-01,Halidol,BCP33202,HALOPERIDOL [HSDB],Tox21_110162,KBioSS_001341, Pms Haloperidol,FT-0669100,Brotopon,McM-JR-1625,DTXSID4034150,HMS1920D03,Halojust,HY-14538,HMS502A16,S1920,HALOPERIDOL [USP IMPURITY],HSDB 3093,Serenase,SCHEMBL8264, Aloperidin,McN-JR-1625,AB00052008_23,HALOPERIDOLUM [WHO-IP LATIN],HMS2091J09,4'-Fluoro-4-[4-hydroxy-4-(4'-chlorophenyl)piperidino]butyrophenone, Einalon S (TN), Haloperidolum,CHA71659,Tox21_300475,Haloperidol,Neurodol, Aloperidol, Eukystol (TN),Haloperidol, Pharmaceutical Secondary Standard; Certified Reference Material,NCGC00023875-06,SMR000058303,HMS3370H11,CHEBI:5613,Tocris-0931,Haloperidol, powder,SR-01000003076-2, Halopal,NCGC00015500-08,BDBM21398,177716-59-5,HALOPERIDOL [VANDF],SBI-0050565.P004,NCGC00015500-04,Halopidol,Haloperidol for system suitability,4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone,Prestwick0_000115, Halopoidol,CCRIS 1630,STL417208,SR-01000003076,NCGC00015500-05,NCGC00016234-01, Peluces,HALOPERIDOL [USP-RS],Dozic,Pharmakon1600-01500325,Fortunan,NCGC00015500-16, Eukystol,Aloperidon,gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorobutyrophenone,DSSTox_CID_14150,HALOPERIDOL COMPONENT OF VESALIUM,W-105791,NSC-170973, R 1625, Uliolind,HALOPERIDOL [JAN],Peluces,4-(4-Hydroxy-4'-chloro-4-phenylpiperidino)-4'-fluorobutyrophenone,Haloperidolum [INN-Latin],Linton,J6292F8L3D,C01814,HMS1568G12, Pernox,Picroside-III, Halojust,4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,KBio2_003909, Peluces (TN), Fortunan,Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard,Mixidol,NSC 170973,Eukystol,NCGC00015500-03,HALOPERIDOL [WHO-IP],Pekuces,AT13670, Vesalium,A0H334,Z1590789254,Lopac-H-1512,Oprea1_509923,NSC615296,HALOPERIDOL [USP MONOGRAPH],Spectrum2_001268, Sigaperidol (TN),SR-01000003076-8


Estimated data

Solubility: -4.201 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 49.3% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.